"Clinical benefit rate" in phase 2 gynecologic cancer trials: implying more than the data support?
Gynecol Oncol
.
2010 May;117(2):348-9.
doi: 10.1016/j.ygyno.2010.01.004.
Epub 2010 Feb 18.
Author
Maurie Markman
1
Affiliation
1
Department of Gynecologic Medical Oncology, University of Texas MD Anderson Cancer, Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. mmarkman@mdanderson.org
PMID:
20167354
DOI:
10.1016/j.ygyno.2010.01.004
No abstract available
MeSH terms
Clinical Trials, Phase II as Topic / methods*
Endpoint Determination
Female
Genital Neoplasms, Female / drug therapy*
Humans
Treatment Outcome